<div id="readability-page-1"><p><span>Novo Nordisk A/S (NYSE:NVO - Get Free Report)</span> was downgraded by stock analysts at UBS Group from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a report issued on Tuesday,Finviz reports.</p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><ul><li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li></ul><p>Other equities analysts have also recently issued research reports about the stock. HSBC cut shares of Novo Nordisk A/S from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $57.00 price target on the stock. in a research report on Thursday, July 31st. BMO Capital Markets  reissued a &#34;market perform&#34; rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Dbs Bank cut shares of Novo Nordisk A/S to a &#34;sell&#34; rating in a report on Friday, April 25th. BNP Paribas started coverage on shares of Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an &#34;underperform&#34; rating on the stock. Finally, Guggenheim cut shares of Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, ten have assigned  a hold rating and two have issued  a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and a consensus target price of $93.67.</p><p><b>View Our Latest Stock Analysis on NVO</b></p><h2>Novo Nordisk A/S Stock Performance</h2><ul><li>Will Hims &amp; Hers Fall Along With Novo Nordisk?</li></ul><p>NYSE:NVO opened at $48.86 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56. The firm has a 50-day moving average of $68.89 and a two-hundred day moving average of $72.37. The stock has a market cap of $218.15 billion, a P/E ratio of 14.46, a PEG ratio of 1.46 and a beta of 0.63. Novo Nordisk A/S has a 1-year low of $46.90 and a 1-year high of $139.74. </p><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion for the quarter.  On average, research analysts expect that  Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year. </p><h2>Institutional Investors Weigh In On Novo Nordisk A/S</h2><ul><li>3 Biotech Stocks to Watch: Iovance, Neurocrine &amp; Viking</li></ul><p>Hedge funds have recently made changes to their positions in the business. North Star Investment Management Corp. raised its holdings in shares of  Novo Nordisk A/S by 18.2% during the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after buying an additional 3,200 shares during the last quarter.  Bank of New York Mellon Corp raised its holdings in  Novo Nordisk A/S by 6.0% during the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock worth $58,316,000 after purchasing an additional 47,804 shares in the last quarter.  Stanley Laman Group Ltd. bought a new stake in  Novo Nordisk A/S during the first quarter worth approximately $390,000.  Dover Advisors LLC bought a new stake in  Novo Nordisk A/S during the first quarter worth approximately $505,000.  Finally, GAMMA Investing LLC raised its holdings in  Novo Nordisk A/S by 9.6% during the first quarter. GAMMA Investing LLC now owns 9,466 shares of the company's stock worth $657,000 after purchasing an additional 827 shares in the last quarter. Institutional investors own  11.54% of the company's stock. </p><h2>Novo Nordisk A/S Company Profile</h2> (Get Free Report)<p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><h2>See Also</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Manufacturing Stocks Investing</li><li>3 Reasons the Market Can Rally, 2 Ways to Diversify If It Doesn't</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>A New AI Tailwind Could Come to Boost Taiwan Semiconductor Stock</li><li>What is an Earnings Surprise?  </li><li>Analysts Make a Quantum Bet on D-Wave's Cryogenic Packaging </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>UBS Group has downgraded Novo Nordisk A/S from a "buy" to a "neutral" rating. Other analysts have also adjusted their ratings, with HSBC lowering it to "hold" and BMO Capital Markets to "market perform". Currently, the stock has an average rating of "Hold" with a consensus target price of $93.67. Novo Nordisk's stock opened at $48.86, with a market cap of $218.15 billion and a P/E ratio of 14.46. The company reported $11.87 billion in revenue for the last quarter, with an EPS of $0.92.</p>

UBS Group Downgrades Novo Nordisk A/S (NYSE:NVO) to Neutral